{
    "meta": {
        "portal_name": "pharmacodynamics",
        "language": "en",
        "updated": "20150503"
    },
    "schema": {
        "html:portal": "http://en.recuweb.com/pharmacodynamics/",
        "graph:videos": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/videos.json",
        "graph:news": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/news.json",
        "graph:blogs": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/blogs.json"
    },
    "items": {
        "chipleybugle.com/2015/05/pharmacy-researchers-get-grants-to-study-hormones-role-in-stress-mood": {
            "title": "Pharmacy researchers get grants to study hormones role in stress, mood disorders...",
            "snippet": "Frazier is an associate professor and Krause is an assistant professor in the College of Pharmacys department of pharmacodynamics. Their work also may reveal more about why bingeing on certain foods can feel so good. Oxytocin, which facilitates...",
            "date": "2015-05-01",
            "categories": "foods,food,college,pharmacodynamics",
            "tags": "pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/chipleybugle.com/2015/05/pharmacy-researchers-get-grants-to-study-hormones-role-in-stress-mood",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://chipleybugle.com/2015/05/01/pharmacy-researchers-get-grants-to-study-hormones-role-in-stress-mood-disorders/"
        },
        "concordy.com/2015/04/biotech-company-moving-to-downtown-schenectady-concordiensis": {
            "title": "Biotech company moving to downtown Schenectady - Concordiensis...",
            "snippet": "Biotech company moving to downtown SchenectadyConcordiensisThe Institute for Clinical Pharmacodynamics recently relocated its office and laboratory to a new mixed-use building in downtown Schenectady. ICPD specializes in improving the development...",
            "date": "2015-04-30",
            "categories": "pharmacodynamics,institute",
            "tags": "clinical,pharmacodynamics,company",
            "recuweb_url": "http://en.recuweb.com/institute/concordy.com/2015/04/biotech-company-moving-to-downtown-schenectady-concordiensis",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://concordy.com/news/2015/04/biotech-company-moving-to-downtown-schenectady/"
        },
        "nature.com/2015/04/patent-watch-have-the-biosimilar-floodgates-been-opened-in-united-states": {
            "title": "Patent watch: Have the biosimilar floodgates been opened in the United States? -...",
            "snippet": "Patent watch: Have the biosimilar floodgates been opened in the United States?... including the assessment of immunogenicity and pharmacokinetics and pharmacodynamics. However, even if a biosimilar product can clear these two BPCIA hurdles, it may...",
            "date": "2015-04-30",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "biosimilar,product,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/nature.com/2015/04/patent-watch-have-the-biosimilar-floodgates-been-opened-in-united-states",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://nature.com/nrd/journal/v14/n5/full/nrd4622.html"
        },
        "biopharma-reporter.com/2015/04/regulators-skip-clinical-data-and-extrapolate-biosimilar-indications": {
            "title": "Regulators: skip clinical data and extrapolate biosimilar indications -...",
            "snippet": ": skip clinical data and extrapolate biosimilar and pharmacodynamics endpoints are usually more sensitive to product differences than clinical data. We still have sponsors who identify analytical differences between their biosimilar and the original...",
            "date": "2015-04-29",
            "categories": "pharmacodynamics",
            "tags": "sponsors,sponsors-who-identify,identify,identify-analytical,identify-analytical-differences,analytical,analytical-differences,analytical-differences-between,differences,differences-between,between,between-their-biosimilar,biosimilar,original,endpoints,endpoints-are-usually,usually,usually-more-sensitive,sensitive,sensitive-to-product,product,product-differences,differences-than-clinical,clinical,clinical-data,data,skip,skip-clinical,skip-clinical-data,data-and-extrapolate,extrapolate,extrapolate-biosimilar,extrapolate-biosimilar-indications,biosimilar-indications,indications,regulators,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/biopharma-reporter.com/2015/04/regulators-skip-clinical-data-and-extrapolate-biosimilar-indications",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://biopharma-reporter.com/Markets-Regulations/Regulators-skip-clinical-data-and-extrapolate-biosimilar-indications"
        },
        "fnno.com/2015/04/nektar-therapeutics-makes-a-move-down-4-4%": {
            "title": "Nektar Therapeutics Makes a Move: Down 4.4%...",
            "snippet": "Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. There is potential upside of...",
            "date": "2015-04-28",
            "categories": "metabolism,drugs,pharmacokinetics,pharmacodynamics,life",
            "tags": "metabolism,distribution,drug,benefits,therapeutics,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/life/fnno.com/2015/04/nektar-therapeutics-makes-a-move-down-4-4%",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics%2Bpharmacodynamics&format=RSS&cc=us",
            "source_url": "http://fnno.com/story/market-movers/331-nektar-therapeutics-makes-move-down-44-auto-generated"
        },
        "in-pharmatechnologist.com/2015/04/regulators-skip-clinical-data-and-extrapolate-biosimilar-indications": {
            "title": "Regulators: skip clinical data and extrapolate biosimilar indications...",
            "snippet": "Pharmacokinetics and pharmacodynamics endpoints are usually more sensitive to product differences than clinical data. We still have sponsors who identify analytical differences between their biosimilar and the original biologic and dont see the...",
            "date": "2015-04-28",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "sponsors,sponsors-who-identify,identify,identify-analytical,identify-analytical-differences,analytical,analytical-differences,analytical-differences-between,differences,differences-between,between,between-their-biosimilar,biosimilar,original,endpoints,endpoints-are-usually,usually,usually-more-sensitive,sensitive,sensitive-to-product,product,product-differences,differences-than-clinical,clinical,clinical-data,data,skip,skip-clinical,skip-clinical-data,data-and-extrapolate,extrapolate,extrapolate-biosimilar,extrapolate-biosimilar-indications,biosimilar-indications,indications,regulators,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/in-pharmatechnologist.com/2015/04/regulators-skip-clinical-data-and-extrapolate-biosimilar-indications",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://in-pharmatechnologist.com/Regulatory-Safety/Regulators-skip-clinical-data-and-extrapolate-biosimilar-indications"
        },
        "satprnews.com/2015/04/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-satellite": {
            "title": "Late-Breaking Oral Presentation at The International Liver Congress (ILC... - Satellite PR News...",
            "snippet": "Late-Breaking Oral Presentation at The International Liver Congress (ILC...Satellite PR News (press release)Regulus also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy volunteers, the...",
            "date": "2015-04-25",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "healthy,healthy-volunteers,volunteers,presentations,presentations-highlighting,highlighting,oral,regulus,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/satprnews.com/2015/04/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-satellite",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics&output=atom&nord=1",
            "source_url": "http://satprnews.com/2015/04/25/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-2015-highlights-rg-101s-potent-durable-and-pan-genotypic-effects-in-diverse-hcv-population/"
        },
        "rttnews.com/2015/04/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101": {
            "title": "Regulus Therapeutics Presents New Data Strengthening Profile Of RG-101...",
            "snippet": "Regulus noted that it also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy volunteers, the preclinical pharmacokinetics, pharmacodynamics, and toxicity of RG-101, and the efficacy of...",
            "date": "2015-04-25",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "healthy,healthy-volunteers,volunteers,presentations,presentations-highlighting,highlighting,regulus,therapeutics,data,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/rttnews.com/2015/04/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics%2Bpharmacodynamics&format=RSS&cc=us",
            "source_url": "http://rttnews.com/2487502/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101.aspx"
        },
        "medpagetoday.com/2015/04/tabalumab-offers-no-clinical-benefits-to-ra-patients": {
            "title": "Tabalumab Offers No Clinical Benefits to RA Patients...",
            "snippet": "Despite clear pharmacodynamics changes as evidenced by changes in CD20 B cells, RF rheumatoid factor, and immunoglobulins following tabalumab treatment, BAFF inhibition with tabalumab was not clinically, functionally, or structurally efficacious...",
            "date": "2015-04-24",
            "categories": "pharmacodynamics",
            "tags": "treatment,clinical,benefits,patients,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/medpagetoday.com/2015/04/tabalumab-offers-no-clinical-benefits-to-ra-patients",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://medpagetoday.com/Rheumatology/Arthritis/51186"
        },
        "4-traders.com/2015/04/genzyme-commences-phase-2a-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme: Commences Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease...",
            "snippet": "Genzyme, a Sanofi company, reported that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment of Fabry...",
            "date": "2015-04-23",
            "categories": "therapy,pharmacodynamics",
            "tags": "oral,treatment,clinical,patients,company,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/4-traders.com/2015/04/genzyme-commences-phase-2a-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://4-traders.com/GENZYME-CORPORATION-4875/news/Genzyme--Commences-Phase-2a-Clinical-Trial-to-Evaluate-Oral-Therapy-for-Fabry-Disease-20250405/"
        }
    }
}